Sources: 44NIH Clinical Center, 4ClinicalTrials, 6Cochrane Library, 65UMLS, 43NDF-RT, 13DrugBank, 26HMDB, 9DGIdb, 53PharmGKB, 30IUPHAR, 47Novoseek, 1BitterDBSee all MalaCards sources |
Drugs for Progressive Multifocal Leukoencephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 57)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Natalizumab | approved, investigational | Phase 4 | 93 | 189261-10-7 | | 189261-10-7 Anti-VLA4 Anti-alpha4 integrin | D06886 Natalizumab Natalizumab (INN) Tysabri Tysabri (TN) |
| | 2 | | Methylprednisolone | approved | Phase 4 | 1082 | 83-43-2 | 6741 | (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione .DELTA.1-6.alpha.-Methylhydrocortisone 1-Dehydro-6alpha-methylhydrocortisone 1-dehydro-6alpha-Methylhydrocortisone 1-dehydro-6α-methylhydrocortisone 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 121673-01-6 4-08-00-03498 (Beilstein Handbook Reference) 46436_FLUKA 46436_RIEDEL 570-35-4 6 Methylprednisolone 6-Methylprednisolone 6-alpha-Methylprednisolone 6.alpha.-Methylprednisolone 6923-42-8 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 6alpha-Methylprednisolone 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 83-43-2 A-methapred AC1L1N7A Artisone-Wyeth Artisone-wyeth BPBio1_000174 BRD-K35240538-001-03-1 BRN 2340300 BSPBio_000158 Besonia Bio-0658 CHEBI:6888 CHEMBL650 CID6741 CPD000058330 D00407 D008775 DB00959 Depo-Medrol (acetate) Depo-medrol Dopomedrol EINECS 201-476-4 Esametone Firmacort HMS1568H20 HMS2090B13 HSDB 3127 LMST02030178 LS-118498 Lemod M0639_SIGMA M1665 MEPRDL MLS000028541 MLS001148159 MLS002207191 Medesone Medixon Medlone 21 | Medrate Medrol Medrol (TN) Medrol Adt Pak Medrol Dosepak Medrol adt pak Medrol dosepak Medrol, Solu-Medrol, Medrone, Methylprednisolone Medrone Mesopren Metastab Methyleneprednisolone Methylprednisolon Methylprednisolone Methylprednisolone (JP15/USP/INN) Methylprednisolone [USAN:INN:BAN:JAN] Methylprednisolone, 6-alpha Methylprednisolonum Methylprednisolonum [INN-Latin] Metilbetasone Metilprednisolona Metilprednisolona [INN-Spanish] Metilprednisolone Metilprednisolone [DCIT] Metilprednisolone [Dcit] Metipred Metrisone Metrocort Metysolon Moderin MolPort-002-528-554 NCGC00022735-03 NCI60_001657 NSC-19987 NSC19987 Nirypan Noretona Predni N Tablinen Prednol- L Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI) Prestwick0_000279 Prestwick1_000279 Prestwick2_000279 Prestwick3_000279 Prestwick_622 Promacortine Reactenol S1733_Selleck SAM002589984 SMR000058330 SPBio_002377 Sieropresol Solomet Solu-medrol Summicort Suprametil U 7532 UNII-X4W7ZR7023 Urbason Urbasone Wyacort ZINC03875560 delta(1)-6alpha-Methylhydrocortisone delta(sup 1)-6-alpha-Methylhydrocortisone methylprednisolone methylprenisolone | |
| | 3 | | Prednisolone | approved | Phase 4 | 1082 | 50-24-8 | 5755 | (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione .DELTA.1-Cortisol .DELTA.1-Dehydrocortisol .DELTA.1-Dehydrohydrocortisone .DELTA.1-Hydrocortisone .delta.-Cortef .delta.-Stab 1,2-Dehydrohydrocortisone 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol 1-Dehydrocortisol 1-Dehydrohydrocortisone 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene 46656_FLUKA 46656_RIEDEL 50-24-8 58201-11-9 8056-11-9 AC-1773 AC1L1L2E Ak-Pred Ak-Tate Alphadrol Articulose-50 BPBio1_000164 BRD-K98039984-001-03-0 BRN 1354103 BSPBio_000148 Bio-0666 Bubbli-Pred C07369 CCRIS 980 CHEBI:8378 CHEMBL131 CID5755 CO-Hydeltra CPD000718761 Co-Hydeltra Codelcortone Cordrol Cortalone Cotogesic Cotolone D00472 D011239 DB00860 Decaprednil Decortin H Delcortol Delta F Delta(1)-dehydrohydrocortisone Delta-Cortef Delta-Cortef (TN) Delta-Ef-Cortelan Delta-Stab Delta-stab Deltacortenol Deltacortril Deltacortril Enteric Deltahydrocortisone Deltasolone Deltisilone Depo-Medrol Derpo PD Derpo Pd Dexa-Cortidelt Hostacortin H Dexa-Cortidelt hostacortin H Di Adreson F Di-Adreson F Di-Adreson-F Di-adreson F DiAdresonF Dicortol Donisolone Dydeltrone EINECS 200-021-7 Eazolin D Econopred Econopred Plus Erbacort Erbasona Estilsona Fernisolone Fernisolone P Fernisolone-P Flamasone Flo-pred HMS1568H10 HMS2090J05 HSDB 3385 Hostacortin H Hydeltra Hydeltra-Tba Hydeltrasol Hydeltrone Hydrodeltalone Hydrodeltisone Hydroretrocortin Hydroretrocortine I-Pred Inflamase Forte Inflamase Mild K 1557 Key-Pred Klismacort LMST02030179 LS-7669 Lentosone Lite Pred M-Predrol MLS001304083 | MLS002154250 MLS002207037 Medrol Medrol Acetate Metacortandralone Methylprednisolone Acetate Meti-Derm Meticortelone Metreton Millipred MolPort-002-507-147 NCGC00179649-01 NSC 9120 NSC9120 NSC9900 Neo-Delta-Cortef Nisolone Nor-Pred T.B.A. Ocu-Pred Ocu-Pred Forte Omnipred Ophtho-Tate Orapred P0152_SIGMA P0637 P6004_SIGMA PRDL PRED-G Panafcortelone Paracortol Paracotol Pediapred Poly-Pred Precortalon Precortancyl Precortilon Precortisyl Pred Forte Pred Mild Predair Predair A Predair Forte Predalone 50 Predalone T.B.A. Predate Predate Tba Predate-50 Predcor-25 Predcor-50 Predcor-Tba Predisolone Sodium Phosphate Predne-Dome Prednelan Predni-Dome Prednicen Predniliderm Predniretard Prednis Prednisolona Prednisolona [INN-Spanish] Prednisolone Prednisolone (JP15/USP/INN) Prednisolone (anhydrous) Prednisolone Acetate Prednisolone Sodium Phosphate Prednisolone Tebutate Prednisolone [INN:BAN:JAN] Prednisolonum Prednisolonum [INN-Latin] Predonin Predonine Prelone Prenolone Prestwick0_000274 Prestwick1_000274 Prestwick2_000274 Prestwick3_000274 Prestwick_404 Rolisone S1737_Selleck SAM002264639 SMR000718761 SPBio_002367 Scherisolon Solone Steran Sterane Sterolone Supercortisol UNII-9PHQ9Y1OLM Ulacort Ultra Pred Ultracorten H Ultracortene H Ultracortene-H Ultracortene-Hydrogen Ultracortene-hydrogen ZINC03833821 component of Ataraxoid component of K-Predne-Dome delta(1)-Cortisol delta(1)-Dehydrocortisol delta(1)-Dehydrohydrocortisone delta(1)-Hydrocortisone delta(sup 1)-Cortisol delta(sup 1)-Dehydrocortisol delta(sup 1)-Dehydrohydrocortisone delta(sup 1)-Hydrocortisone delta-dehydrocortisol delta-dehydrohydrocortisone delta-hydrocortisone prednisolone | |
| | 4 | | Interferon beta-1b | approved | Phase 4 | 82 | 145155-23-3 | | | Fibroblast interferon IFN-beta Interferon beta precursor | |
| | 5 | | Antiviral Agents | | Phase 4, Phase 2 | 8071 | | | | 6 | | Anti-Infective Agents | | Phase 4, Phase 2, Phase 1 | 17220 | | | | 7 | | Gastrointestinal Agents | | Phase 4, Phase 2 | 6401 | | | | 8 | | Immunologic Factors | | Phase 4, Phase 2 | 18483 | | | | 9 | | Immunosuppressive Agents | | Phase 4, Phase 2 | 10422 | | | | 10 | | interferons | | Phase 4 | 1930 | | | | 11 | | Interferon-beta | | Phase 4 | 253 | | | | 12 | | Prednisolone acetate | | Phase 4 | 1082 | | | | 13 | | Protective Agents | | Phase 4 | 5651 | | | | 14 | | Peripheral Nervous System Agents | | Phase 4 | 18510 | | | | 15 | | Prednisolone hemisuccinate | | Phase 4 | 1082 | | | | 16 | | Prednisolone phosphate | | Phase 4 | 1082 | | | | 17 | | Antineoplastic Agents, Hormonal | | Phase 4 | 4256 | | | | 18 | | glucocorticoids | | Phase 4 | 3896 | | | | 19 | | Anti-Inflammatory Agents | | Phase 4 | 8478 | | | | 20 | | Antiemetics | | Phase 4 | 3213 | | | | 21 | | Neuroprotective Agents | | Phase 4 | 1376 | | | | 22 | | Hormone Antagonists | | Phase 4 | 10002 | | | | 23 | | Fingolimod Hydrochloride | | Phase 4 | 86 | | | | 24 | | Methylprednisolone Hemisuccinate | | Phase 4 | 1082 | | | | 25 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 4 | 9988 | | | | 26 | | Methylprednisolone acetate | | Phase 4 | 1082 | | | | 27 | | Hormones | | Phase 4 | 11748 | | | | 28 | | Adjuvants, Immunologic | | Phase 4 | 1783 | | | | 29 | | Vedolizumab | approved | Phase 2 | 37 | 943609-66-3 | | | | 30 | | Cytarabine | approved, investigational | Phase 2 | 1035 | 147-94-4 | 6253 | (beta-D-Arabinofuranosyl)cytosine (beta-D-arabinofuranosyl)cytosine 1-.beta.-D-arabinofuranosyl-cytosine 1-Arabinofuranosylcytosine 1-beta -D-Arabinofaranosylcytosine 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta -D-Arabinofuranosylcytosine 1-beta-D-Arabinofaranosylcytosine 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone 1-beta-D-Arabinofuranosyl-Cytosine 1-beta-D-Arabinofuranosylcytosine 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside 1-beta-D-Arabinosyl-Cytosine 1-beta-D-Arabinosylcytosine 147-94-4 1beta -Arabinofuranasylcytosine 1beta -D-Arabinofuranosylcytosine 1beta -D-Arabinosylcytosine 1beta-Arabinofuranasylcytosine 1beta-D-Arabinofuranosylcytosine 1beta-D-Arabinosylcytosine 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS] 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl 30399_FLUKA 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech] 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech] 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one 69-74-9 (hydrochloride) AC-1075 AC1L1M4F AC1Q52OJ AI3-52329 AR3 Alexan Ara-C Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine Ara-Cytidine AraC Arabinocytidine Arabinofuranosyl Cytidine Arabinofuranosylcytosine Arabinosyl Cytosine Arabinosylcytosine Arabitin Aracytidine Aracytin Aracytine Arafcyt BIDD:GT0371 BIDD:PXR0139 BTB15125 Beta-cytosine arabinoside C02961 C1768_SIGMA C2035 C9H13N3O5 CCRIS 913 CHEBI:28680 CHEMBL803 CHX 3311 CID6253 CPD000449317 CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9) Citarabina Citarabina [INN-Spanish] Cytarabin Cytarabina Cytarabine Cytarabine (JP15/USP/INN) | Cytarabine [USAN:INN:BAN:JAN] Cytarabine liposome injection Cytarabinoside Cytarabinum Cytarabinum [INN-Latin] Cytarbel Cytonal Cytosar Cytosar-U Cytosine 1-beta-D-arabinofuranoside Cytosine arabinofuranoside Cytosine arabinose Cytosine arabinoside Cytosine arabinoside (VAN) Cytosine beta-D-arabinofuranoside Cytosine beta-D-arabinofuranoside hydrochloride Cytosine beta-D-arabinoside Cytosine, beta -D-arabinoside Cytosine, beta-D-arabinoside Cytosine-1-beta-D-arabinofuranoside Cytosine-1-beta-D-arabinofuranoside hydrochloride Cytosine-beta -D-arabinofuranoside Cytosine-beta -arabinoside Cytosine-beta-D-arabinofuranoside Cytosine-beta-arabinoside Cytosinearabinoside D00168 DB00987 DepoCyte Depocyt Depocyt (TN) Depocyt (liposomal) Depocyte EINECS 205-705-9 Erpalfa FT-0082880 HMS2051K19 HMS2090A18 HSDB 3049 Intrathecal (injected into the spinal fluid) DepoCyt Intrathecal cytarabine (also known as ara-C) Iretin LS-860 Lopac0_000316 MLS000758310 MLS001066340 MolPort-001-792-509 NCGC00093356-03 NCGC00093356-04 NCGC00093356-05 NCI-C04728 NSC 287459 NSC287459 S1648_Selleck SAM001247012 SMR000449317 SR-01000075773-3 Spongocytidine TL8001048 Tarabine U 19920A U-19,920 U-19920 UNII-04079A1RDZ Udicil ZINC03795098 beta -D-arabinosylcytosine beta -arabinosylcytosine beta -cytosine arabinoside beta-Ara C beta-Ara c beta-Arabinosylcytosine beta-Cytosine arabinoside beta-D-Arabinosylcytosine cytarabine cytarabine liposome injection cytosine-β-D-arabinofuranoside |
| | 31 | | Didanosine | approved | Phase 2 | 150 | 69655-05-6 | 50599 | 149409-57-4 2',3'-Dideoxyinosine 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor 2',3'-Dideoxyinosine & Interferon-.alpha. 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein) 2',3'-Dideoxyinosine (AIDS Initiative) 2',3'-Dideoxyinosine (ddI) 2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine 2'3'-DIDEOXYINOSINE 2,3-Dideoxyinosine 2,3-dideoxyinosine 2DI 3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine 69655-05-6 9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one AC-12026 AC1L19ET AC1L3OPK BMY 40900 BMY-40900 BRN 3619529 Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride Bio-0685 C06953 C083832 CCRIS 805 CHEBI:490877 CHEMBL1460 CID119381 CID50599 CPD000058576 D00296 D2I D3066 DB00900 DB02392 DDI DDI and rIFN.alpha.2 DIDEOXYINOSINE DRG-0016 DS-4152 & ddI DdIno Didanosina | Didanosina [INN-Spanish] Didanosine Didanosine (JAN/USAN/INN) Didanosine and Interferon-.alpha.-2 Didanosinum Didanosinum [INN-Latin] Dideoxyinosine Dideoxyinosine (DDI) FT-0082664 HMS2051J11 HMS2089N20 HSDB 6548 Hypoxanthine ddN Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2 Intron A & Videx KS-1049 LOA & ddI Listera ovata agglutinin & 2',3'-Dideoxyinosine MLS000759469 MLS001055350 MLS001424118 MLS002154216 MolPort-002-507-371 MolPort-002-885-819 N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride NCGC00090691-01 NCGC00159514-02 NCGC00159514-03 NCGC00164280-01 NE 100 NE-100 NSC 612049 NSC-612049 NSC612049 PC-SOD+ddI S1702_Selleck SAM001246673 SMR000058576 Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine UNII-K3GDH6OH08 Videx Videx (TN) Videx EC Videx EC(TM)(slow-release capsules) Videx Ec Videx(TM) ZINC13597823 ddI & GM-CSF ddI & IFN-.alpha. ddI & sCD4(rsCD4) ddI + d4T combination ddIno didanosine |
| | 32 | | Tenofovir | approved, investigational | Phase 2 | 666 | 147127-20-6 | 464205 | (R)-9-(2-Phosphonomethoxypropyl)adenine (R)-9-(2-Phosphonylmethoxypropyl)adenine (R)-PMPA 147127-20-6 206184-49-8 AC-760 AC1LA9BO Anh. tenofovir Anhydrous tenofovir Apropovir CHEBI:45809 CHEMBL483 CID464205 D,L-Tenofovir DB00300 GNA & Tenofovir GS 1275 GS 1278 GS1278 HHA & Tenofovir | KS-5021 MolPort-003-850-411 NCGC00167535-01 PMPA PMPA-(R) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI) Phosphonic acid, [[2-(6-amino-9H-purin-9 S1401_Selleck TDF TFV Tenefovir Tenofovir Tenofovir (anh.) Tenofovir Disoproxil Fumarate Tenofovir disoproxil Tenofovir disoproxil fumarate UNII-99YXE507IL Viread Viread, Tenofovir [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid |
| | 33 | | Enfuvirtide | approved, investigational | Phase 2 | 58 | 159519-65-0 | 16130199 | 262434-79-7 C105196 DP178 Dp 178 Enfuvirtide Enfuvirtide [USAN] Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41] Fuzeon HSDB 7341 | LS-183961 N-Acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histadyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide Pentafuside Roche brand of pentafuside T 20 T 20 (peptide) T-20 T-20 cpd T20 peptide UNII-19OWO1T3ZE peptide T20 |
| | 34 | | Zidovudine | approved | Phase 2 | 491 | 30516-87-1 | 35370 | -Azido-3&prime -deoxythymidine 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine 3&prime 3' Azido 2',3' Dideoxythymidine 3' Azido 3' deoxythymidine 3'-Azido-2',3'-Dideoxythymidine 3'-Azido-3'-deoxythymidine 3'-Azido-3'-deoxythymidine & Concanavalin A 3'-Azido-3'-deoxythymidine & Erythropoietin 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19 3'-Azido-3'-deoxythymidine & Interleukin-1 3'-Azido-3'-deoxythymidine & Interleukin-2 3'-Azido-3'-deoxythymidine & Interleukin-6 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon 3'-Azido-3'-deoxythymidine & Sho-Saiko-To 3'-Azido-3'-deoxythymidine (AIDS) 3'-Azido-3'deoxythymidine & Interferon .alpha. 3'-Azidothymidine 3'-Deoxy-3'-azidothymidine 3'-azido-3'-deoxythymidine, AZT 3-Azido-3-deoxythymidine 30516-87-1 399024-19-2 A2169_SIGMA AC1L1TKL AC1Q2OEK AZT AZT & CD4(178)-PE 40 AZT & Colony-stimulating factor 2 AZT & Concanavalin A (ConA) AZT & EPO AZT & GM-CSF AZT & HPA AZT & IFN.alpha. AZT & IL-1 AZT & IL-2 AZT & IL-6 AZT & Interferon-.alpha.-2 AZT & Li & EPO AZT & Li & GM-CSF AZT & Li & IL-1 AZT & Li & IL-6 AZT & Lymphoblastoid Interferon AZT & NP (from PHCA or HSA) AZT & PM-19 AZT & SST AZT & rIFN.alpha.2 AZT & rsCD4 & rIFN.alpha.A AZT & rsT4 AZT & sCD4 AZT & srCD4 AZT (Antiviral) AZT Antiviral AZT TRANSPLACENTAL CARCINOGENESIS STUDY AZT+PRO 140 AZT, Antiviral Antiviral AZT Apo-Zidovudine Azidothymidine Aztec BB_NC-1012 BPBio1_000403 BRD-K72903603-001-04-6 BSPBio_000365 BSPBio_003153 BW A509U BW-A 509U BW-A-509U BW-A509U BWA 509U BWA-509U BWA509U C07210 CCRIS 105 CHEBI:10110 CHEBI:127307 CHEMBL129 CID35370 CPD000058351 | Compound S Cpd S D00413 D015215 DB00495 DRG-0004 DS-4152 & AZT DivK1c_000524 HMS1921J20 HMS2090G11 HMS2092D06 HMS501K06 HSDB 6515 IDI1_000524 Interferon AD + 3'-azido-3'-deoxythymidine Intron A & AZT K7 [P Ti2 W10 O40] KBio1_000524 KBio2_001828 KBio2_004396 KBio2_006964 KBio3_002653 KBioGR_000703 KBioSS_001828 LS-1159 Liposomal AZT-SN-1 Liposomal AZT-SN-3 MLS000028548 MLS001055351 MLS001076358 MLS002153202 MLS002222249 Met-SDF-1.beta. & AZT Met-SDF-1.beta. & Zidovudine MolPort-002-507-286 NCGC00023945-03 NCGC00023945-04 NCGC00023945-05 NCGC00023945-08 NCGC00178237-01 NCGC00178237-02 NINDS_000524 NSC 602670 Novo-Azt PC-SOD+AZT Prestwick3_000333 Propolis+AZT Racemic Liposomal AZT Retrovir Retrovir (TN) Retrovir(TM) SAM002548971 SMR000058351 SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle) SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle) SPBio_000834 SPECTRUM1502109 STK801891 Spectrum2_000927 Spectrum3_001507 Spectrum4_000332 Spectrum5_001101 Spectrum_001348 UNII-4B9XT59T7S ZDV ZIDOVUDINE [AZT] ZINC03779042 ZVD Zidovudin Zidovudina Zidovudina [Spanish] Zidovudine Zidovudine (JAN/USP/INN) Zidovudine EP III Zidovudine [USAN:INN:BAN:JAN] Zidovudine+PRO 140 Zidovudinum Zidovudinum [Latin] antiviral azidodeoxythymidine rIFN-beta seron & AZT racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle) zidovudin zidovudine | |
| | 35 | | Emtricitabine | approved, investigational | Phase 2 | 394 | 143491-57-0 | 60877 | (-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (-)-.beta.-L-FTC (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine (-)-2'-Deoxy-5-fluoro-3'-thiacytidine (-)-FTC (-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone (2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone .beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine 143491-54-7 143491-57-0 145213-48-5 2',3',5-FTC 2',3'-Dideoxy-5-fluoro-3'-thiacytidine 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine 2'-Deoxy-5-fluoro-3'-thiacytidine 2-FTC 3'-Thia-2'.3'-dideoxy-5-fluorocytidine 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone 4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine 524W91 AC1L1U3I AC1Q4KUB BW 1592 | BW 524W91 BW-524W91 BW524W91 C122114 C12599 C8H10FN3O3S CHEBI:31536 CHEMBL885 CID60877 Coviracil Coviracil(TM) D01199 DB00879 DRG-0208 Emtricitabin Emtricitabina Emtricitabine Emtricitabine (JAN/USAN/INN) Emtricitabinum Emtriva Emtriva (TN) Emtriva(TM) FT-0080009 HMS2089I05 HSDB 7337 LS-135838 LS-173184 NCGC00164564-01 RCV Racivir SBB066061 TL8000958 UNII-G70B4ETF4S ZINC03629271 beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine dOTFC emtricitabine |
| | 36 | | Topotecan | approved, investigational | Phase 2 | 330 | 119413-54-6 | 60700 | (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione 123948-87-8 9-Dimethylaminomethyl-10-hydroxycamptothecin 9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin AC-11592 AC1L1TQZ AC1Q6APZ BSPBio_002348 C11158 C23H23N3O5 CCRIS 8163 CHEBI:107501 CHEBI:46035 CHEMBL84 CID60700 D08618 DB01030 HMS2090B20 HSCI1_000228 Hycamptamine Hycamptin Hycamtamine Hycamtin Hycamtin (TN) LS-127395 MLS000759456 | NCGC00178695-01 NCI60_004771 NCIStruc1_001659 NCIStruc2_001796 NChemBio.2007.10-comp24 NSC609699 SK&F-104864-A SKF 104864 SKF-104864-A SKF-S 104864 SMP2_000312 SMP2_000327 SMR000466344 TOPO TOPOTECAN, HYCAMTIN TPT TTC Topotecan Topotecan (BAN) Topotecan Hcl Topotecan Hydrochloride Topotecan Lactone Topotecan Monohydrochloride, (S)-Isomer Topotecan [INN:BAN] Topotecan lactone Topotecane Topotecane [INN-French] Topotecanum Topotecanum [INN-Latin] UNII-7M7YKX2N15 topotecan | |
| | 37 | | Zalcitabine | approved | Phase 2 | 44 | 7481-89-2 | 24066 | .beta.-D-2',3'-Dideoxycytidine .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor .beta.-D-DDC 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine 16803P 2',3'-DIDEOXYCYTIDINE 2',3'-Dideoxycytidine 2',3'-Dideoxycytidine & Interferon.alpha. 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate) 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein) 2,3-dideoxycytidine 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine 36775_FLUKA 4-amino-1-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one 5-25-14-00313 (Beilstein Handbook Reference) 7481-89-2 AC-824 AC1L2N6R BPBio1_001378 BRN 0654956 BSPBio_001253 C07207 C9H13N3O3 CCRIS 692 CHEBI:10101 CHEMBL853 CID24066 CPD000058253 Cytidine, 2',3'-dideoxy- & Colony-stimulating factor Cytidine, 2',3'-dideoxy- & Interferon.alpha. D 5782 D00412 D3581 D5782_SIGMA DB00943 DDC DDC (DDC) DDCYD DS-4152 & ddC Dideoxycytidine EU-0100360 HIVID HMS1548B19 HMS1571O15 HMS2051H18 HMS2090C12 HSDB 7156 Hivid (TN) Hivid(TM) | Hivid, Dideoxycytidine, NSC 606170, Zalcitabine Interferon AD + ddC KS-1130 LS-1645 Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine Lopac0_000360 MLS000069636 MLS000759540 MLS001055363 MLS001424210 MolPort-002-885-873 NCGC00090705-01 NCGC00090705-02 NCGC00090705-03 NCGC00090705-05 NCGC00090705-06 NCGC00090705-07 NCGC00090705-10 NCGC00179242-01 NSC 606170 NSC-606170 NSC606170 PC-SOD & ddC Prestwick0_001037 Prestwick1_001037 Prestwick2_001037 Prestwick3_001037 Ro 24-2027/000 Ro-24-2027/000 S1719_Selleck SAM001246779 SMR000058253 SPBio_003104 SRI-7707 Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine TimTec1_004969 UNII-6L3XT8CB3I UPCMLD-DP115 UPCMLD-DP115:001 ZINC00039906 Zalcitabine (JAN/USP/INN) Zalcitabine [USAN:INN:BAN] Zalcitibine bmse000712 ddC ddC & GM-CSF ddC & IFN.alpha. ddC & Interferon.alpha. ddC & NP (from PHCA or HSA) ddC & sCD4 ddC (Antiviral) ddCyd zalcitabine |
| | 38 | | Mefloquine | approved | Phase 1, Phase 2 | 54 | 53230-10-7 | 4046 | (+)-(11R,2'S)-erythro-Mefloquine (+)-Mefloquine (+)-Threo-Mefloquine (-)-(11S,2'R)-erythro-Mefloquine (-)-Mefloquine (-)-Threo-Mefloquine (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol 49752-90-1 51688-68-7 51742-87-1 51744-84-4 51744-85-5 53230-10-7 68682-27-9 AB00052310 AC1L1HAJ AC1L249S AC1L9UO6 AC1MHD7J AC1MHD7O AC1Q4K1I AR-1G4597 BIDD:GT0596 BIDD:PXR0166 BPBio1_000190 BRD-A89585551-003-03-4 BSPBio_000172 C07633 C17H16F6N2O CAS-51773-92-3 CHEBI:151162 CHEBI:403542 CHEMBL411329 CHEMBL411685 CHEMBL411686 CHEMBL416956 CID3000506 CID3000516 CID4046 CID40692 CID456309 D04895 DB00358 DivK1c_000790 EINECS 256-468-3 Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol HMS1922C09 HMS502H12 HSDB 6853 IDI1_000790 KBio1_000790 KBio2_001792 KBio2_004360 KBio2_006928 KBio3_002046 KBioGR_001392 KBioSS_001792 LS-142023 LS-187797 | Lariam Lariam (Hydrochloride) MQ Mefloquin Mefloquina Mefloquina [INN-Spanish] Mefloquine Mefloquine (USAN/INN) Mefloquine HCL Mefloquine Hydrochloride Mefloquine [USAN:INN:BAN] Mefloquine aziridine Mefloquinone Mefloquinum Mefloquinum [INN-Latin] Mephloquine MolPort-003-981-155 Méfloquine NCGC00016864-01 NCGC00094994-01 NCGC00094994-02 NCGC00094994-03 NCGC00094994-04 NCGC00161831-01 NCGC00161831-02 NINDS_000790 NSC157387 Prestwick0_000126 Prestwick1_000126 Prestwick2_000126 Prestwick3_000126 RO 13-7224 RO 13-7225 RTI1169-1-1 RTI1172-1-1 RTI1173-1-1 RTI1174-1-1 RTI1188-1-1 RTI1189-1-1 Racemic mefloquine Ro 21-5998 Ro 21-5998 (Hydrochloride) Ro 215998 Ro-21-5998-001 SPB-80406 SPBio_001591 SPBio_002111 SPECTRUM1503070 Spectrum2_001516 Spectrum3_000953 Spectrum4_001066 Spectrum5_001122 Spectrum_001312 UNII-TML814419R WR 142490 WR-142,490 WR-142490 WR-177,602 [(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol mefloquine nchembio.215-comp3 nchembio.87-comp20 | |
| | 39 | | Immunoglobulins | | Phase 2 | 4477 | | | | 40 | | Topoisomerase Inhibitors | | Phase 2 | 4081 | | | | 41 | | Antibodies | | Phase 2 | 4477 | | | | 42 | | Anti-Retroviral Agents | | Phase 2 | 2794 | | | | 43 | | topoisomerase I inhibitors | | Phase 2 | 1131 | | | | 44 | | Nucleic Acid Synthesis Inhibitors | | Phase 2 | 3836 | | | | 45 | | Antimetabolites | | Phase 2 | 9454 | | | | 46 | | Reverse Transcriptase Inhibitors | | Phase 2 | 1656 | | | | 47 | | Antimetabolites, Antineoplastic | | Phase 2 | 5770 | | | | 48 | | lenograstim | | Phase 2 | 1134 | | | | 49 | | Antimalarials | | Phase 1, Phase 2 | 1058 | | | | 50 | | Antiparasitic Agents | | Phase 1, Phase 2 | 1854 | | |
Interventional clinical trials: (show all 25)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide | Recruiting | NCT01970410 | Phase 4 | | 2 | Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis | Recruiting | NCT01981161 | Phase 4 | | 3 | Methylprednisolone During the Switch Between Natalizumab and Fingolimod | Recruiting | NCT02769689 | Phase 4 | | 4 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | Terminated | NCT01211665 | Phase 4 | | 5 | Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis | Terminated | NCT01701856 | Phase 4 | | 6 | Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) | Completed | NCT00120367 | Phase 2 | | 7 | Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients | Completed | NCT00001048 | Phase 2 | | 8 | Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) | Completed | NCT00002395 | Phase 2 | | 9 | Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease | Completed | NCT00619489 | Phase 2 | | 10 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | Terminated | NCT00746941 | Phase 1, Phase 2 | | 11 | Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 | Terminated | NCT00655824 | Phase 2 | | 12 | A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection | Completed | NCT00002270 | | | 13 | A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients | Completed | NCT00000945 | | | 14 | Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome | Completed | NCT00342602 | | | 15 | JC Virus Reactivation in Multiple Sclerosis | Completed | NCT02004444 | | | 16 | A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine | Completed | NCT00002274 | | | 17 | JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab | Completed | NCT01070836 | | | 18 | Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort | Completed | NCT01070719 | | | 19 | Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control | Completed | NCT01626248 | | | 20 | Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) | Recruiting | NCT01730131 | | | 21 | Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells | Recruiting | NCT02694783 | Phase 0 | | 22 | Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant | Recruiting | NCT01386359 | | | 23 | Drug Exposure Registry for GSK2248761, an Investigational NNRTI | Active, not recruiting | NCT01458132 | | | 24 | Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML) | Enrolling by invitation | NCT01132053 | | | 25 | Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy | Terminated | NCT01211639 | |
|
